These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8693211)

  • 1. Oral anticoagulant treatment in a medical care district--a descriptive study.
    Jansson JH; Westman G; Boman K; Nilsson T; Norberg B
    Scand J Prim Health Care; 1995 Dec; 13(4):268-74. PubMed ID: 8693211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anticoagulant treatment audited in the south of Sweden. A well functioning practice--which can improve even more].
    Timberg I; Schedvin G; Svensson PJ
    Lakartidningen; 2012 Aug 8-21; 109(32-33):1411-3. PubMed ID: 22953429
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic setting.
    Wittkowsky AK; Nutescu EA; Blackburn J; Mullins J; Hardman J; Mitchell J; Vats V
    Chest; 2006 Nov; 130(5):1385-9. PubMed ID: 17099014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics.
    Wallvik J; Själander A; Johansson L; Bjuhr O; Jansson JH
    Scand J Prim Health Care; 2007 Jun; 25(2):123-8. PubMed ID: 17497491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant treatment of patients in Swedish primary health care. Safety aspects.
    Wändell PE
    Eur J Clin Pharmacol; 2001 Apr; 57(1):61-4. PubMed ID: 11372594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defects of the renal collecting systems in patients receiving anticoagulants.
    Smith WL; Weinstein AG; Wiot JF
    Radiology; 1974 Dec; 113(3):649-51. PubMed ID: 4139731
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral anticoagulant therapies: balancing the risks.
    Nutescu EA
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S3-11. PubMed ID: 23640530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
    Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
    Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The preparation of a patient with long-term anticoagulant cumarin treatment for invasive surgery].
    Penka M; Buliková A; Gumulec J; Matýsková M; Smejkal P; Kissová J; Slechtová M; Chlupová G
    Vnitr Lek; 2006 Mar; 52 Suppl 1():35-40. PubMed ID: 16637448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation therapy: patient management and evaluation of an outpatient clinic.
    Kornblit P; Senderoff J; Davis-Ericksen M; Zenk J
    Nurse Pract; 1990 Aug; 15(8):21-6, 29, 32. PubMed ID: 2398969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.
    Vinogradova Y; Coupland C; Hill T; Hippisley-Cox J
    BMJ; 2018 Jul; 362():k2505. PubMed ID: 29973392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resource consumption and management associated with monitoring of warfarin treatment in primary health care in Sweden.
    Andersson S; Björholt I; Nilsson GH; Krakau I
    BMC Fam Pract; 2006 Nov; 7():67. PubMed ID: 17096858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Audit of an anticoagulant clinic: doctor and patient knowledge.
    McCormack PM; Stinson JC; Hemeryck L; Feely J
    Ir Med J; 1997; 90(5):192-3. PubMed ID: 9345833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of the quality of oral anticoagulation management in an outpatient clinic and in general practices.
    Holm T; Deutch S; Lassen JF; Jastrup B; Husted SE; Heickendorff L
    Thromb Res; 2002 Jan; 105(2):103-8. PubMed ID: 11958799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recommended use of INR in the laboratory monitoring of oral anticoagulant treatment].
    Syrjälä M
    Duodecim; 1998; 114(6):573-5. PubMed ID: 11466922
    [No Abstract]   [Full Text] [Related]  

  • 17. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.
    Hylek EM
    Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532
    [No Abstract]   [Full Text] [Related]  

  • 18. [Oral anticoagulation with vitamin K antagonists].
    Alberio L
    Ther Umsch; 2003 Jan; 60(1):5-9. PubMed ID: 12638470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substantial differences in initiation of oral anticoagulant therapy and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings.
    Mikkelsen AP; Hansen ML; Olesen JB; Hvidtfeldt MW; Karasoy D; Husted S; Johnsen SP; Brandes A; Gislason G; Torp-Pedersen C; Lamberts M
    Europace; 2016 Apr; 18(4):492-500. PubMed ID: 26443443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.
    Wieloch M; Själander A; Frykman V; Rosenqvist M; Eriksson N; Svensson PJ
    Eur Heart J; 2011 Sep; 32(18):2282-9. PubMed ID: 21616951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.